Floatz logo

Ysch-01

Malignant Glioma

Darell BignerPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

40 Active assets in the Malignant Glioma cohort.

Asset / SponsorPhaseRating
Irinotecan
Kailin Yang, MD, PhD
Phase 2BB
(+)-VINCRISTINE
Kailin Yang, MD, PhD
Phase 2BB
Marizomib
Aadi Bioscience, Inc.
Phase 2BB
Valaciclovir
Trogenix ltd
Phase 2BB
Hycamtin
Jeffrey N. Bruce
Phase 2B

View all 50 →

Same molecule, other indications

Ysch-01 is also rated in:

cancerDormant
CC
Indicative ·
45 / 100
View asset →
metastatic malignant neoplasmDormant
CC
Indicative ·
43 / 100
View asset →
Advanced Solid TumorsDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →